• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TEOXANE RHA2; RESILIENT HYALURONIC ACID

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TEOXANE RHA2; RESILIENT HYALURONIC ACID Back to Search Results
Device Problem Off-Label Use (1494)
Patient Problem Obstruction/Occlusion (2422)
Event Type  Injury  
Event Description
Vascular occlusion, vascular occlusion.Rha2 to the mid face, off label use.United states report received from other health care professional on 08-jun-2022.A registered nurse who was also the prescriber/injector, reported that a male patient of unknown age received rha2 for unknown indication on (b)(6) 2022 (dose and frequency not reported).An unknown volume of rha2 were applied to the mid face area using an unknown injection technique.It was unknown if the needle from the box was used for the administration or cannula was used for rha2 administered.Previous cosmetic procedures were not provided.No medical history was not provided.Concomitant medication and food supplement were not provided.On (b)(6) 2022, a patient was injected with an unknown amount of rha2 to the "mid face".On an unknown date in 2022, the patient had an "occlusion" at the injection site, that was described as in red color.The area was flushed with hyaluronidase as treatment.The event resolved on an unknown date in 2022.The outcome of the event was recovered the intensity of the event was not provided.The product was not available for return.(b)(4).No additional information was available at the time of this report.Case comment: a causal relationship between the rha2 and vascular occlusion is assessed as possible based on the compatible temporal relationship and the lack of alternative etiologies that can be identified based on the reported information.The company will continue monitoring the benefit-risk profile for the product.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
RHA2
Type of Device
RESILIENT HYALURONIC ACID
Manufacturer (Section D)
TEOXANE
les charmilles
rue de lyon, 105
geneva, CH-12 03
SZ  CH-1203
MDR Report Key14882271
MDR Text Key295119171
Report Number3007772056-2022-00014
Device Sequence Number1
Product Code LMH
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Distributor
Reporter Occupation Non-Healthcare Professional
Type of Report Initial
Report Date 07/01/2022,06/08/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/01/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Was the Report Sent to FDA? Yes
Date Report Sent to FDA07/01/2022
Distributor Facility Aware Date06/08/2022
Device Age0 YR
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Other;
Patient SexMale
Patient RaceWhite
-
-